Shares of Jubilant Pharmova dropped nearly 6% to the day’s low of Rs 908 on BSE after the company reported a decline of 45% year-on-year (YoY) in consolidated profit to Rs 56 crore in the first quarter ended June.

According to a filing with the exchange, the reported profit decreased YoY due to lower operating profitability and increase in depreciation for Line 3 in Spokane.

The revenue went up 17% on yearly basis to Rs 2,229 crore against Rs 1,901 crore in the same time period a year ago on the back of strong performance across all business segments, with CDMO Sterile Injectables delivering particularly robust growth.

The total income jumped 18% to Rs 2,249 crore against Rs 1,913 crore in Q1FY26. The other income for Q1’FY27 includes grant income of Rs 5.6 crore for Line 3, which shall continue for more than 20 years and upto 30 years.

EBITDA decreased YoY, particularly due to unavailability of SPECT products in Radiopharmaceuticals & negligible third party revenues and higher operating expenses including incremental remediation cost at CMO Montreal.

"We are pleased to announce revenue of Rs. 2,229 Cr. for Q1’FY27, which reflects a solid growth of 17% on YoY basis. Revenue growth is broad based across all our business segments, but particularly strong in CDMO Sterile Injectables on the back of technology transfer revenues from the new & third line. EBITDA for the quarter stands at Rs 268 crore,” said Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman & Non-Executive Director, Jubilant Pharmova.

Segmental business performance

Radiopharma: Radiopharmaceuticals Q1’FY27 revenue grew by 19% to Rs. 322 Cr. and EBITDA for the period stood at Rs. 110 Cr. EBITDA margins decreased YoY due to unavailability of certain SPECT products. By H2’FY27, all the SPECT Radiopharmaceutical products are expected to be available. Radiopharmacy Q1’FY27 revenue grew by 17% YoY to Rs. 700 Cr. on the back of an increase in volume from certain PET products. EBITDA for the period grew by 19% to Rs. 12 Cr.

Allergy Immunotherapy : As the sole supplier of Venom in the US, we are expanding the overall market by increasing customer awareness. In Q1’FY27, revenues grew by 18% to Rs. 214 Cr., driven by strong growth in the US & outside US markets. EBITDA grew by 5% to Rs. 66 Cr. EBITDA margins reduced YoY due to lower production.

CDMO Sterile Injectables : Q1’FY27 revenue grew by 34% to Rs. 496 Cr. due to incremental revenue from Line 3. EBITDA for the period stood at Rs. 45 Cr. EBITDA margins were lower YoY due to negligible third-party revenues & higher operating expenses including incremental remediation cost at Montreal facility.

CRDMO : In Q1’FY27, the Drug Discovery business revenue grew by 8% to Rs. 174 Cr. EBITDA for the period grew by 43% to Rs. 45 Cr. EBITDA margins expanded by 630 basis points to 26%. In the API business, revenue for Q1’FY27 stood at Rs. 135 Cr. EBITDA for the period stood at Rs. 19 Cr. Revenue and EBITDA margins decreased YoY due to the industry wide pricing pressure.

Generics : In Q1’FY27, the Generics business revenue grew by 4% to Rs. 173 Cr on the back of launch of 2 new products. EBITDA for the period stood at Rs. 4 Cr. EBITDA margins decreased YoY due to change in product mix. Looking ahead, we are preparing to launch multiple products in FY27 to drive revenue growth & profitability.

Proprietary Novel Drugs : The global clinical trials for our lead programs, Phase I/II trial for JBI -802 for Essential Thrombocythemia (ET) and other Myeloproliferative Neoplasms (MPN) and Phase I trial for JBI -778 for non-small cell lung cancer (NSCLC), Adenoid Cystic Carcinoma and high-grade Glioma are actively enrolling patients and progressing in line with our expectations

While sharing the Vision 2030, the company expects the revenue to reach 2x from FY24 to FY30. EBITDA margin is expected between 23% to 25% by FY30.